{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T08:14:20Z","timestamp":1787904860743,"version":"build-2784847793"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R25DA033211"],"award-info":[{"award-number":["R25DA033211"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R25DA0123582"],"award-info":[{"award-number":["R25DA0123582"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["T32AI052074"],"award-info":[{"award-number":["T32AI052074"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["1UL1TR001430"],"award-info":[{"award-number":["1UL1TR001430"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.jsat.2016.12.010","type":"journal-article","created":{"date-parts":[[2016,12,29]],"date-time":"2016-12-29T22:16:22Z","timestamp":1483049782000},"page":"65-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":206,"special_numbering":"C","title":["Long-term retention in Office Based Opioid Treatment with buprenorphine"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8116-6023","authenticated-orcid":false,"given":"Zoe M.","family":"Weinstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunjoong W.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie M.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen T.","family":"Labelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari-Lynn","family":"Drainoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara S.","family":"Bachman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H.","family":"Samet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jsat.2016.12.010_bb0005","doi-asserted-by":"crossref","DOI":"10.1001\/archinternmed.2010.541","article-title":"Collaborative care of opioid-addicted patients in primary care using buprenorphine: Five-year experience","volume":"171","author":"Alford","year":"2011","journal-title":"Archives of Internal Medicine"},{"issue":"4","key":"10.1016\/j.jsat.2016.12.010_bb0010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1300\/J069v24n04_04","article-title":"Racial and ethnic diversity among a heroin and cocaine using population: Treatment system utilization","volume":"24","author":"Bernstein","year":"2005","journal-title":"Journal of Addictive Diseases"},{"issue":"3","key":"10.1016\/j.jsat.2016.12.010_bb0015","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1465-3362.2011.00321.x","article-title":"Mapping the recovery stories of drinkers and drug users in Glasgow: Quality of life and its associations with measures of recovery capital","volume":"31","author":"Best","year":"2012","journal-title":"Drug and Alcohol Review"},{"issue":"1","key":"10.1016\/j.jsat.2016.12.010_bb0020","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004714-199502000-00008","article-title":"Buprenorphine treatment of refractory depression","volume":"15","author":"Bodkin","year":"1995","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.jsat.2016.12.010_bb0025","series-title":"Standard disenrollment assessment form, opioid treatment, version 12","author":"Bureau of Substance Abuse Services","year":"2012"},{"issue":"4","key":"10.1016\/j.jsat.2016.12.010_bb0030","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/add.12834","article-title":"A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia","volume":"110","author":"Burns","year":"2015","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.jsat.2016.12.010_bb0035","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jsat.2013.08.016","article-title":"Referral for substance abuse treatment and depression improvement among patients with co-occurring disorders seeking behavioral health services in primary care","volume":"46","author":"Chan","year":"2014","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"4","key":"10.1016\/j.jsat.2016.12.010_bb0040","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/ADM.0b013e31829727b2","article-title":"Prior buprenorphine experience is associated with office-based buprenorphine treatment outcomes","volume":"7","author":"Cunningham","year":"2013","journal-title":"Journal of Addiction Medicine"},{"issue":"1","key":"10.1016\/j.jsat.2016.12.010_bb0045","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00005053-200301000-00003","article-title":"Psychiatric comorbidity and the prevalence of HIV infection in a sample of patients in treatment for substance abuse","volume":"191","author":"Dausey","year":"2003","journal-title":"The Journal of Nervous and Mental Disease"},{"issue":"1\u20132","key":"10.1016\/j.jsat.2016.12.010_bb0050","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2012.12.010","article-title":"Patient characteristics associated with buprenorphine\/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study","volume":"131","author":"Dreifuss","year":"2013","journal-title":"Drug and Alcohol Dependence"},{"issue":"5","key":"10.1016\/j.jsat.2016.12.010_bb0055","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/ADM.0000000000000057","article-title":"Factors affecting noncompliance with buprenorphine maintenance treatment","volume":"8","author":"Fareed","year":"2014","journal-title":"Journal of Addiction Medicine"},{"issue":"1","key":"10.1016\/j.jsat.2016.12.010_bb0060","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1521-0391.2013.12074.x","article-title":"Predictive factors for relapse in patients on buprenorphine maintenance","volume":"23","author":"Ferri","year":"2014","journal-title":"The American Journal on Addictions"},{"issue":"2","key":"10.1016\/j.jsat.2016.12.010_bb0065","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1080\/10550490701860971","article-title":"Long-term treatment with buprenorphine\/naloxone in primary care: Results at 2\u20135Years","volume":"17","author":"Fiellin","year":"2008","journal-title":"The American Journal on Addictions"},{"issue":"2","key":"10.1016\/j.jsat.2016.12.010_bb0070","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1080\/08897077.2013.819828","article-title":"A comparison of characteristics and outcomes of opioid-dependent patients initiating office-based buprenorphine or methadone maintenance treatment","volume":"35","author":"Fingerhood","year":"2014","journal-title":"Substance Abuse"},{"issue":"2","key":"10.1016\/j.jsat.2016.12.010_bb0075","first-page":"126","article-title":"Does psychiatric comorbidity affect drug abuse treatment outcome? A prospective assessment of drug abuse, treatment tenure and infectious diseases in an Israeli methadone maintenance clinic","volume":"43","author":"Gelkopf","year":"2006","journal-title":"The Israel Journal of Psychiatry and Related Sciences"},{"issue":"1","key":"10.1016\/j.jsat.2016.12.010_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2006.05.012","article-title":"Substance abuse treatment entry, retention, and outcome in women: A review of the literature","volume":"86","author":"Greenfield","year":"2007","journal-title":"Drug and Alcohol Dependence"},{"issue":"2","key":"10.1016\/j.jsat.2016.12.010_bb0085","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3109\/00952990.2013.842241","article-title":"Baseline characteristics and treatment outcomes in prescription opioid dependent patients with and without co-occurring psychiatric disorder","volume":"40","author":"Griffin","year":"2014","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"issue":"3","key":"10.1016\/j.jsat.2016.12.010_bb0090","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jsat.2013.10.004","article-title":"Leaving buprenorphine treatment: Patients' reasons for cessation of care","volume":"46","author":"Gryczynski","year":"2014","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/j.jsat.2016.12.010_bb0095","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/add.12333","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial","volume":"109","author":"Hser","year":"2014","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2016.12.010_bb0100","doi-asserted-by":"crossref","DOI":"10.1111\/add.13238","article-title":"Long-term outcomes after randomization to buprenorphine\/naloxone versus methadone in a multi-site trial","author":"Hser","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2016.12.010_bb0105","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/1472-6963-10-352","article-title":"Responses of Massachusetts hospitals to a state mandate to collect race, ethnicity and language data from patients: A qualitative study","volume":"10","author":"Jorgensen","year":"2010","journal-title":"BMC Health Services Research"},{"issue":"9358","key":"10.1016\/j.jsat.2016.12.010_bb0110","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0140-6736(03)12600-1","article-title":"1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo-controlled trial","volume":"361","author":"Kakko","year":"2003","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.jsat.2016.12.010_bb0115","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1001\/archpsyc.1994.03950010008002","article-title":"Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey","volume":"51","author":"Kessler","year":"1994","journal-title":"Archives of General Psychiatry"},{"issue":"4","key":"10.1016\/j.jsat.2016.12.010_bb0120","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/ADM.0b013e3182312983","article-title":"Statement of the American Society of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction","volume":"5","author":"Kraus","year":"2011","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.jsat.2016.12.010_bb0125","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jsat.2015.06.010","article-title":"Office-based opioid treatment with buprenorphine (OBOT-B): Statewide implementation of the Massachusetts collaborative care model in community health centers","volume":"60","author":"LaBelle","year":"2016","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"5","key":"10.1016\/j.jsat.2016.12.010_bb0130","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/add.13270","article-title":"Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization","volume":"111","author":"Lo-Ciganic","year":"2016","journal-title":"Addiction"},{"issue":"1\u20133","key":"10.1016\/j.jsat.2016.12.010_bb0135","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.drugalcdep.2008.07.018","article-title":"Alcohol and opioid dependence medications: Prescription trends, overall and by physician specialty","volume":"99","author":"Mark","year":"2009","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/j.jsat.2016.12.010_bb0140","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0376-8716(00)00155-1","article-title":"Predictors of outpatient treatment retention: Patient versus substance use characteristics","volume":"62","author":"McCaul","year":"2001","journal-title":"Drug & Alcohol Dependence"},{"key":"10.1016\/j.jsat.2016.12.010_bb0145","series-title":"Encyclopedia of database systems","first-page":"679","article-title":"Data warehousing for clinical research","author":"Murphy","year":"2009"},{"issue":"1","key":"10.1016\/j.jsat.2016.12.010_bb0150","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3109\/00952990.2014.983274","article-title":"Association between hepatitis C virus and opioid use while in buprenorphine treatment: Preliminary findings","volume":"41","author":"Murphy","year":"2015","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"key":"10.1016\/j.jsat.2016.12.010_bb0155","series-title":"Buprenorphine","author":"Office of Diversion Control, Drug & Chemical Evaluation Section, Drug Enforcement Administration","year":"2013"},{"key":"10.1016\/j.jsat.2016.12.010_bb0160","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12888-015-0415-z","article-title":"Buprenorphine maintenance program with contracted work\/education and low tolerance for non-prescribed drug use: A cohort study of outcome for women and men after seven years","volume":"15","author":"\u00d6hlin","year":"2015","journal-title":"BMC Psychiatry"},{"issue":"11","key":"10.1016\/j.jsat.2016.12.010_bb0165","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1001\/archpsyc.1985.01790340050008","article-title":"Untreated opiate addicts: How do they differ from those seeking treatment?","volume":"42","author":"Rounsaville","year":"1985","journal-title":"Archives of General Psychiatry"},{"issue":"8","key":"10.1016\/j.jsat.2016.12.010_bb0170","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/ajad.12292","article-title":"The impact of addiction medications on treatment outcomes for persons with co-occurring PTSD and opioid use disorders","volume":"24","author":"Saunders","year":"2015","journal-title":"The American Journal on Addictions"},{"issue":"1\u20133","key":"10.1016\/j.jsat.2016.12.010_bb0175","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.drugalcdep.2012.06.020","article-title":"Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine\/naloxone treatment","volume":"127","author":"Savant","year":"2013","journal-title":"Drug and Alcohol Dependence"},{"issue":"8","key":"10.1016\/j.jsat.2016.12.010_bb0180","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/archpsyc.1997.01830200041006","article-title":"Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse","volume":"54","author":"Schottenfeld","year":"1997","journal-title":"Archives of General Psychiatry"},{"issue":"11","key":"10.1016\/j.jsat.2016.12.010_bb0185","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/j.1525-1497.2005.0228.x","article-title":"Buprenorphine retention in primary care","volume":"20","author":"Stein","year":"2005","journal-title":"Journal of General Internal Medicine"},{"key":"10.1016\/j.jsat.2016.12.010_bb0190","author":"Substance Abuse and Mental Health Services Administration"},{"key":"10.1016\/j.jsat.2016.12.010_bb0195","series-title":"Medicaid coverage and financing of medications to treat alcohol and opioid use disorders. HHS publication no. SMA-14-4854","author":"Substance Abuse and Mental Health Services Administration","year":"2014"},{"issue":"1","key":"10.1016\/j.jsat.2016.12.010_bb0200","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1521-0391.2009.00003.x","article-title":"The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine\/naloxone for the treatment of opioid dependence","volume":"19","author":"Sullivan","year":"2010","journal-title":"The American Journal on Addictions"},{"issue":"1","key":"10.1016\/j.jsat.2016.12.010_bb0205","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1521-0391.2011.00186.x","article-title":"Compliance with buprenorphine medication-assisted treatment and relapse to opioid use","volume":"21","author":"Tkacz","year":"2012","journal-title":"The American Journal on Addictions"},{"issue":"2","key":"10.1016\/j.jsat.2016.12.010_bb0210","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/10550881003684582","article-title":"Women and addiction: The importance of gender issues in substance abuse research","volume":"29","author":"Tuchman","year":"2010","journal-title":"Journal of Addictive Diseases"},{"key":"10.1016\/j.jsat.2016.12.010_bb0215","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.02.030","article-title":"Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network prescription opioid addiction treatment study","volume":"150","author":"Weiss","year":"2015","journal-title":"Drug and Alcohol Dependence"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547216303658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547216303658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:46:02Z","timestamp":1760039162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547216303658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":43,"alternative-id":["S0740547216303658"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2016.12.010","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term retention in Office Based Opioid Treatment with buprenorphine","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2016.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}